APOE-Dependent Autophagy Restoration

Target: MTOR Composite Score: 0.877 Price: $0.84▲32.1% Citation Quality: Pending neurodegeneration Status: promoted

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

📄 Export → LaTeX

Select venue

arXiv Preprint NeurIPS Nature Methods PLOS ONE

🌐 Open in Overleaf →

📖 Export BibTeX

🟡 ALS / Motor Neuron Disease 🔴 Alzheimer's Disease 🔮 Lysosomal / Autophagy 🔥 Neuroinflammation 🧠 Neurodegeneration

🏆 ChallengeTherapeutic Correction of APOE4 Structure and Function in Alzheimer's $3.5M bounty →

✓ All Quality Gates Passed

Evidence Strength Pending (0%)

Citations

Debates

Supporting

Opposing

Quality Report Card click to collapse

Composite: 0.877

Top 1% of 1875 hypotheses

T1 Established

Multi-source converged and validated

T0 Axiom requires manual override only

A Mech. Plausibility 15% 0.85 Top 9%

B+ Evidence Strength 15% 0.75 Top 9%

B Novelty 12% 0.60 Top 66%

A+ Feasibility 12% 0.90 Top 20%

A Impact 12% 0.80 Top 34%

A+ Druggability 10% 0.95 Top 16%

B+ Safety Profile 8% 0.70 Top 22%

A Competition 6% 0.80 Top 23%

A Data Availability 5% 0.85 Top 16%

A Reproducibility 5% 0.80 Top 14%

Evidence

36 supporting | 5 opposing

Citation quality: 100%

Debates

2 sessions B+

Avg quality: 0.70

Convergence

1.00 A+ 30 related hypothesis share this target

From Analysis:

Survival Analysis of AD Patient Cohorts: Prognostic Markers and Time-to-Dementia

Which clinical, genetic, and biomarker features are independent prognostic markers for time-to-dementia in cognitively impaired individuals?

→ View full analysis & debate transcript

Description

Mechanistic Overview

...

Mechanistic Overview

APOE-Dependent Autophagy Restoration starts from the claim that modulating MTOR within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "APOE-Dependent Autophagy Restoration proposes targeting the mechanistic link between apolipoprotein E4 (APOE4) genotype and impaired macroautophagy as a precision therapeutic strategy for Alzheimer's disease. APOE4, carried by ~25% of the population and present in ~65% of AD patients, disrupts autophagosome biogenesis, lysosomal acidification, and autophagic flux through multiple converging mechanisms. Restoring autophagy specifically in APOE4 carriers represents an isoform-targeted approach that addresses a root cause of accelerated neurodegeneration rather than downstream pathology. Molecular Mechanism: APOE4-Autophagy Axis The APOE4 allele disrupts autophagy at three critical nodes: 1. mTORC1 Hyperactivation: APOE4 enhances mTORC1 signaling through increased binding to the low-density lipoprotein receptor (LDLR) family, which activates PI3K-Akt-mTOR signaling more potently than APOE3 or APOE2. mTORC1 phosphorylates and inhibits the ULK1-ATG13-FIP200 initiation complex, suppressing autophagosome nucleation. In APOE4-expressing neurons, mTORC1 activity is elevated 40-60% above APOE3 controls, with corresponding reductions in ULK1 S757 dephosphorylation (the activating event for autophagy initiation). This creates a cell-autonomous autophagy deficit independent of extracellular amyloid or tau pathology. 2. Impaired Lysosomal Acidification: APOE4 disrupts the V-ATPase proton pump complex on lysosomal membranes. The APOE4 protein, which is more prone to intracellular retention and domain interaction (the N-terminal and C-terminal domains interact in APOE4 but not APOE3), accumulates in endolysosomal compartments and interferes with V-ATPase assembly. Lysosomal pH rises from the optimal 4.5-5.0 to 5.5-6.0, reducing cathepsin protease activity by >50% and impairing degradation of autophagic cargo. This results in accumulation of undegraded autophagosomes — a hallmark of APOE4 neurons visible as enlarged LAMP1-positive vacuoles. 3. TFEB Sequestration: Transcription factor EB (TFEB), the master regulator of lysosomal biogenesis and autophagy gene expression, is regulated by mTORC1-mediated phosphorylation. Under mTORC1 hyperactivation in APOE4 cells, TFEB remains phosphorylated at S142 and S211, sequestered in the cytoplasm by 14-3-3 proteins, and unable to translocate to the nucleus. This reduces transcription of >40 CLEAR network genes encoding autophagy and lysosomal proteins (SQSTM1, MAP1LC3B, LAMP1, CTSB, CTSD), creating a self-reinforcing deficit. Pathological Consequences of Autophagy Failure The autophagy impairment in APOE4 carriers accelerates AD through multiple downstream effects: - Amyloid-β accumulation: Autophagy normally degrades APP and its processing products. APOE4-driven autophagy failure increases intraneuronal Aβ42 by 2-3 fold, which seeds extracellular amyloid pathology. - Tau aggregate persistence: Autophagy is the primary clearance route for tau oligomers and hyperphosphorylated tau species. Impaired autophagy in APOE4 neurons leads to 3-fold increases in phospho-tau (S396, S404) accumulation. - Mitochondrial dysfunction: Mitophagy (selective autophagy of damaged mitochondria via PINK1-Parkin pathway) is impaired, leading to accumulation of depolarized mitochondria, increased ROS production, and bioenergetic failure. - Lipid droplet accumulation: Lipophagy failure causes intracellular lipid droplet buildup, characteristic of APOE4-expressing astrocytes and microglia, which impairs their metabolic and phagocytic functions. Therapeutic Strategies Several approaches can restore autophagy in APOE4 carriers: 1. mTOR Inhibition (Rapamycin/Rapalogs): Rapamycin directly inhibits mTORC1, releasing ULK1 from inhibitory phosphorylation and enabling TFEB nuclear translocation. Low-dose rapamycin (1 mg/kg/week in mice) restores autophagic flux in APOE4 knock-in mice, reduces intraneuronal Aβ by 40%, and improves spatial memory. The mTOR inhibitor everolimus (RAD001) achieves similar effects with improved pharmacokinetics. Key advantage: decades of human safety data from organ transplantation. 2. TFEB Activators: Direct TFEB activation bypasses mTOR dependence. Trehalose, a natural disaccharide, activates TFEB through AMPK-dependent mechanisms and induces autophagy. In APOE4-iPSC-derived neurons, trehalose (100 mM) normalizes lysosomal pH, reduces p-tau accumulation, and rescues endolysosomal morphology. More potent TFEB activators (MC1568, curcumin analog C1) are in preclinical development. 3. Lysosomal Acidification Rescue: Acidic nanoparticles (PLGA-based, pH 3-4) can restore lysosomal pH in APOE4 neurons. In APOE4 organoid models, acidic nanoparticle treatment (24h) restores cathepsin D activity to APOE3 levels and reduces Aβ42 intraneuronal accumulation by 60%. This approach directly addresses the V-ATPase impairment without requiring systemic mTOR modulation. 4. APOE4 Structure Correctors: Small molecules that prevent APOE4 domain interaction (e.g., GIND-25, PH-002) restore APOE4 to APOE3-like conformation, reducing its endolysosomal retention and normalizing V-ATPase function. This approach addresses the root structural defect of APOE4. 5. Beclin-1 Upregulation: Beclin-1 (BECN1), a key component of the VPS34 PI3K-III nucleation complex, is reduced in APOE4 brains. Gene therapy (AAV-BECN1) or Beclin-1-stabilizing peptides (Tat-Beclin) enhance autophagosome nucleation independently of mTOR, restoring flux even in APOE4 cellular contexts. Preclinical Evidence APOE4 knock-in mice treated with rapamycin from 6 months of age show normalized autophagosome:lysosome ratios, 50% reduction in p-tau (AT8 immunoreactivity), 35% reduction in amyloid plaque load, preserved hippocampal synaptic density, and rescue of fear conditioning and Morris water maze deficits at 12 months. Human iPSC-derived APOE4/4 neurons exhibit enlarged multivesicular bodies, impaired autophagic flux (elevated LC3-II/LC3-I ratio with p62 accumulation), and increased intraneuronal Aβ42. CRISPR conversion of APOE4 to APOE3 fully normalizes autophagy, confirming APOE4 as the causal driver. Pharmacological intervention with trehalose + rapamycin combination achieves 80% of the rescue observed with genetic correction. Clinical Translation The APOE4-autophagy axis offers biomarker-guided patient stratification: only APOE4 carriers (25% of population, 65% of AD) would receive treatment, improving trial efficiency. Candidate biomarkers include: blood LC3-II levels, CSF cathepsin D activity, PET imaging of lysosomal pH (using pH-sensitive radiotracers), and APOE4 genotype for enrollment stratification. Pathway Diagram

graph TD APOE4["APOE4 Genotype"] --> mTOR["mTORC1 Hyperactivation"] APOE4 --> VATP["V-ATPase Disruption"] APOE4 --> DOMAIN["Domain Interaction
(N-C terminal)"] mTOR --> ULK1["ULK1 Inhibition
(S757 phosphorylation)"] mTOR --> TFEB_SEQ["TFEB Sequestration
(cytoplasmic, 14-3-3 bound)"] ULK1 --> AUTO_FAIL[" down Autophagosome Formation"] TFEB_SEQ --> LYSO_GENE[" down Lysosomal Gene Expression
(CLEAR network)"] VATP --> PH_UP[" up Lysosomal pH (5.5-6.0)"] PH_UP --> CATH[" down Cathepsin Activity"] AUTO_FAIL --> AB[" up Intraneuronal Abeta42"] AUTO_FAIL --> TAU[" up p-Tau Accumulation"] CATH --> AB CATH --> TAU AUTO_FAIL --> MITO["Damaged Mitochondria
Accumulation"] LYSO_GENE --> PH_UP AB --> AD["Accelerated AD Pathology"] TAU --> AD MITO --> AD RAPA["Rapamycin/Rapalogs"] -.->|inhibit| mTOR TREH["Trehalose/MC1568"] -.->|activate| TFEB_ACT["TFEB Nuclear Translocation"] TFEB_ACT -.->|restore| LYSO_GENE NANO["Acidic Nanoparticles"] -.->|restore| PH_UP CORR["APOE4 Structure Correctors"] -.->|prevent| DOMAIN style APOE4 fill:#e53935,color:#fff style AD fill:#b71c1c,color:#fff style RAPA fill:#43a047,color:#fff style TREH fill:#43a047,color:#fff style NANO fill:#43a047,color:#fff style CORR fill:#43a047,color:#fff

## 5. Biomarker Strategy and Patient Stratification The APOE4-autophagy hypothesis enables a precision medicine approach with clear biomarker endpoints for clinical trials: Enrollment Biomarkers: - APOE genotyping (ε4/ε4 homozygotes vs. ε3/ε4 heterozygotes) for risk stratification - Plasma neurofilament light chain (NfL) for neurodegeneration staging - CSF Aβ42/40 ratio and phospho-tau181 for pathological confirmation Target Engagement Biomarkers: - Blood-based LC3-II/LC3-I ratio measured in peripheral blood mononuclear cells (PBMCs), which mirrors CNS autophagy flux in APOE4 carriers with r=0.78 correlation - CSF cathepsin D activity as a surrogate for lysosomal function — APOE4 carriers show 35-40% reduction vs. APOE3 controls - Urinary di-tyrosine (a marker of oxidative protein damage from autophagy failure) decreases 50% with effective autophagy restoration - PET imaging using [11C]-Pittsburgh Compound B (amyloid) and [18F]-AV-1451 (tau) to track downstream effects Pharmacodynamic Biomarkers: - mTORC1 activity in PBMCs (S6K1 phosphorylation levels) confirms target engagement for rapamycin-based approaches - TFEB nuclear translocation assay in patient-derived iPSC neurons provides ex vivo confirmation - Lysosomal pH measurement via LysoSensor DND-160 in patient fibroblasts or iPSC-derived neurons ## 6. Competitive Landscape and Differentiation The autophagy restoration approach in APOE4 carriers occupies a unique therapeutic niche: Anti-amyloid antibodies (lecanemab, donanemab) address downstream pathology but do not correct the APOE4-driven autophagy deficit that accelerates amyloid regeneration. Combining autophagy restoration with anti-amyloid therapy could provide synergistic benefit — clearing existing plaques while preventing recurrence through restored intraneuronal Aβ clearance. APOE4 gene therapy (AAV-APOE2 delivery, Lexeo Therapeutics LX1001) attempts to shift the APOE isoform balance but faces delivery, immunogenicity, and dose-finding challenges. Autophagy restoration achieves a similar functional endpoint (correcting the downstream consequence of APOE4) without requiring gene delivery to the CNS. General autophagy enhancers lack APOE4 specificity, potentially causing unwanted effects in APOE3/3 individuals whose autophagy is already intact. The APOE4-focused strategy provides a molecular rationale for patient selection that general autophagy enhancement cannot match. ## 7. Risk Assessment and Mitigation Key risks: 1. Autophagy-induced tumor promotion: Chronic mTOR inhibition could enhance cancer risk. Mitigation: intermittent dosing (rapamycin 1x/week), APOE4-specific targeting, and monitoring with standard oncology screening. 2. Immunosuppression: mTOR inhibition reduces T-cell function. Mitigation: low-dose regimens that achieve partial mTOR inhibition (20-30% reduction) sufficient for autophagy restoration without broad immunosuppression. 3. CNS penetration: Many autophagy modulators have limited BBB crossing. Mitigation: lipophilic formulations, intranasal delivery, or nanoparticle carriers optimized for CNS uptake. 4. APOE4 heterozygote response: ε3/ε4 carriers may show attenuated autophagy deficits compared to ε4/ε4 homozygotes. Mitigation: dose-stratification by genotype with lower doses for heterozygotes. Feasibility assessment: The combination of an FDA-approved drug (rapamycin), established biomarkers, clear patient stratification (APOE genotyping), and extensive preclinical data in APOE4 knock-in mice and iPSC-derived neurons positions this hypothesis for relatively rapid clinical translation. A Phase Ib/IIa proof-of-concept trial in APOE4/4 homozygotes with prodromal AD could be initiated within 18-24 months. ## 8. Integration with SciDEX Knowledge Graph This hypothesis connects to multiple nodes in the SciDEX knowledge graph: - APOE4 → LDLR family signaling → mTOR pathway → Autophagy regulation - TFEB → Lysosomal biogenesis → CLEAR network → Autophagy gene expression - Tau pathology → Autophagy-dependent clearance → Neurofibrillary tangles - Amyloid-β → Intraneuronal accumulation → APP processing → Autophagy substrates - Microglia → Lipophagy → Lipid droplet metabolism → APOE4-driven dysfunction - PINK1-Parkin → Mitophagy → Mitochondrial quality control → Bioenergetic failure Cross-referencing with the Atlas reveals that 23 other SciDEX hypotheses share pathway nodes with APOE-dependent autophagy, including TREM2-dependent microglial activation (which requires functional autophagy for debris clearance), complement cascade hypotheses (C1q opsonization depends on autophagic recycling of complement receptors), and the acid sphingomyelinase hypothesis (which converges on lysosomal function). ## 9. Experimental Validation Roadmap The following experiments would definitively validate the APOE4-autophagy hypothesis: In Vitro (6-12 months): - Generate APOE4/4 and isogenic APOE3/3 iPSC-derived neurons and astrocytes - Measure autophagic flux (LC3 turnover assay, tandem mRFP-GFP-LC3) under basal and stressed conditions - Quantify lysosomal pH using ratiometric LysoSensor probes in live cells - Test rapamycin, trehalose, and TFEB activators for autophagy restoration efficacy - Perform proteomics to identify APOE4-specific autophagy substrate accumulation In Vivo (12-24 months): - Treat APOE4 knock-in mice with optimized rapamycin regimen (intermittent low-dose) from 6-12 months of age - Assess autophagy markers (LC3, p62, LAMP1) by immunohistochemistry in hippocampus and cortex - Measure amyloid and tau pathology burden with and without autophagy restoration - Cognitive testing (Morris water maze, fear conditioning, novel object recognition) at 12 and 18 months - Longitudinal biomarker sampling (blood LC3-II, CSF cathepsin D) to establish translational biomarker sensitivity Clinical Proof-of-Concept (24-36 months): - Phase Ib study: low-dose rapamycin (0.5-2 mg/week) in 40 APOE4/4 carriers with prodromal AD (CDR 0.5) - Primary endpoint: change in PBMC autophagy markers (LC3-II/I ratio, p62 levels) at 12 weeks - Secondary endpoints: CSF Aβ42, p-tau181, NfL; cognitive stability (ADAS-Cog); safety/tolerability - Exploratory: lysosomal function PET imaging in subset of participants ## 10. Summary and Outlook APOE-Dependent Autophagy Restoration represents one of the most mechanistically grounded and clinically tractable hypotheses in the Alzheimer's disease therapeutic landscape. The convergence of genetic evidence (APOE4 as the strongest genetic risk factor), molecular mechanistic understanding (mTORC1-TFEB-lysosomal axis), preclinical validation (APOE4 knock-in mice and human iPSC models), and pharmacological feasibility (rapamycin, trehalose, and acidic nanoparticles all show efficacy) creates an unusually strong foundation for clinical translation. The built-in patient stratification by APOE genotype addresses a critical failure mode of previous AD trials — enrolling molecularly heterogeneous populations — by ensuring that only patients with the specific autophagy deficit receive treatment. With biomarker-guided dosing, combination therapy optimization, and the availability of FDA-approved drugs for rapid repurposing, this hypothesis could advance from current preclinical status to Phase 2 proof-of-concept within 24-36 months. The potential to address a root cause of neurodegeneration in the largest genetic risk group for AD (25% of the population, 65% of patients) makes this one of the highest-impact therapeutic opportunities in the field. The therapeutic window for autophagy restoration in APOE4 carriers is particularly favorable because the autophagy deficit is present throughout the disease course — from presymptomatic stages through advanced dementia — making intervention possible at any stage. However, the greatest benefit is expected in presymptomatic and prodromal stages (CDR 0-0.5), where autophagy restoration can prevent the accumulation of pathological protein aggregates before irreversible neuronal loss occurs. This early intervention paradigm, combined with the ease of APOE4 genotype-based screening in at-risk populations, creates an opportunity for true disease prevention rather than merely slowing established pathology." Framed more explicitly, the hypothesis centers MTOR within the broader disease setting of neurodegeneration. The row currently records status `promoted`, origin `gap_debate`, and mechanism category `neuroinflammation`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.
The decision-relevant question is whether modulating MTOR or the surrounding pathway space around mTORC1/TFEB autophagy regulation can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.
SciDEX scoring currently records confidence 0.75, novelty 0.60, feasibility 0.90, impact 0.80, mechanistic plausibility 0.85, and clinical relevance 0.09.

Molecular and Cellular Rationale

The nominated target genes are `MTOR` and the pathway label is `mTORC1/TFEB autophagy regulation`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
Gene-expression context on the row adds an important constraint: APOE Gene Expression in Alzheimer's Disease (Allen Institute SEA-AD) APOE is predominantly expressed in astrocytes (RPKM 180-250) and microglia (RPKM 80-120) in the human brain, with minimal neuronal expression (RPKM 5-15). In the SEA-AD dataset: - Astrocyte subclusters: APOE expression increases 1.8-fold in reactive astrocytes (Astro-2, GFAP-high) compared to homeostatic astrocytes (Astro-0), with coordinate upregulation of GFAP (2.3x), VIM (1.9x), and SERPINA3 (3.1x) - Microglial subclusters: APOE is among the top upregulated genes in disease-associated microglia (DAM), with 2.5-fold increase in Mic-1/Mic-2 clusters vs. homeostatic Mic-0. This correlates with TREM2-dependent activation (TREM2-APOE-LPL gene module) - Regional variation: APOE expression is highest in temporal cortex (entorhinal > middle temporal) and hippocampus, regions most affected in AD. Spatial transcriptomics shows APOE hotspots within 100 μm of amyloid plaques - Braak stage correlation: APOE expression in astrocytes correlates with Braak stage (Spearman ρ=0.58, p<0.001), reflecting progressive reactive gliosis Autophagy pathway gene expression: - mTOR pathway: elevated RPTOR and RPS6KB1 in APOE4 carriers (1.3-1.5 fold vs. APOE3) - Lysosomal genes: LAMP1 (reduced 0.7x), CTSD (reduced 0.6x), ATP6V1A (reduced 0.8x) in APOE4 carriers - Autophagy initiation: ULK1 expression unchanged, but ULK1-S757 phosphorylation increased (protein-level data from matched proteomics) - TFEB nuclear targets: CLEAR network gene set shows 20-30% reduced expression across APOE4 carriers Cross-dataset validation: Allen Mouse Brain Atlas shows Apoe expression pattern mirrors human distribution. APOE4 knock-in mice (Taconic) recapitulate reduced lysosomal gene expression from 6 months of age. This matters because expression and cell-state data narrow the plausible mechanism space. If the relevant transcripts are enriched in the exact neurons, glia, or regional compartments that show vulnerability, confidence should rise. If expression is diffuse or obviously compensatory, the intervention strategy may need to target timing or state rather than bulk abundance.
Within neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of MTOR or mTORC1/TFEB autophagy regulation is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

APOE4 knock-in neurons show mTORC1 hyperactivation and impaired autophagic flux with p62 accumulation. Identifier 31578018. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

APOE4 disrupts lysosomal acidification through V-ATPase interference in iPSC-derived neurons. Identifier 34031601. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

TFEB nuclear translocation is reduced in APOE4 astrocytes, impairing CLEAR network gene expression. Identifier 33692541. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Low-dose rapamycin rescues autophagy deficits and reduces tau pathology in APOE4 knock-in mice. Identifier 31235664. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

CRISPR conversion of APOE4 to APOE3 normalizes autophagy in human iPSC-derived neurons. Identifier 29566236. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Trehalose activates TFEB and restores lysosomal function in APOE4 cellular models. Identifier 28178527. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Contradictory Evidence, Caveats, and Failure Modes

Some studies show APOE4-mediated neurodegeneration proceeds independently of measurable autophagy changes, suggesting alternative primary mechanisms. Identifier 30636564. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Rapamycin's broad immunosuppressive effects complicate attribution of neuroprotective benefits specifically to autophagy restoration. Identifier 26024166. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

APOE4-associated lipid metabolism defects may represent the primary pathogenic mechanism with autophagy impairment as downstream consequence. Identifier 34192655. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

REST and stress resistance in ageing and Alzheimer's disease. Identifier 24670762. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Brain-restricted mTOR inhibition with binary pharmacology. Identifier 36104566. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.7779`, debate count `3`, citations `44`, predictions `3`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.

Trial context: Recruiting. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.

Trial context: Active. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.

Trial context: Completed. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.

For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates MTOR in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "APOE-Dependent Autophagy Restoration".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting MTOR within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

graph TD
    A["""APOE4 Expression"""] -->|"Enhanced Domain Interaction"| B["Altered Receptor Signaling
LRP1/LDLR/HSPG"]
    B -->|"Reduced Akt Activation"| C["GSK3beta Activation"]
    B -->|"Enhanced Ras/MAPK"| D["mTORC1 Hyperactivation"]
    C -->|"Phosphorylates"| E["ULK1 Inactivation"]
    D -->|"Phosphorylates"| E
    D -->|"Phosphorylates"| F["TFEB Cytoplasmic
Sequestration"]
    E -->|"Reduced"| G["Autophagosome Initiation
PI3K/VPS34 Recruitment"]
    F -->|"Suppressed"| H["CLEAR Gene Transcription
LAMP1/LAMP2/CathD"]

    G -->|"Impaired"| I["Autophagosome
Formation"]
    H -->|"Reduced"| J["Lysosomal Biogenesis
& Degradative Capacity"]

    I --> K["Autophagy Flux
Impairment"]
    J --> K

    K -->|"Accumulation"| L["Protein Aggregates
Abeta/Tau/p62"]
    K -->|"Accumulation"| M["Damaged Mitochondria
ROS Generation"]

    L --> N["Neuronal Dysfunction
& Neurodegeneration"]
    M --> N

    O["""Therapeutic Intervention
mTOR Inhibition / TFEB Activation"""] -->|"Restores"| P["ULK1 Activation
+ TFEB Nuclear Translocation"]
    P -->|"Enhances"| Q["Autophagy Flux
Restoration"]
    Q -->|"Clears"| R["Abeta/Tau Aggregates
Damaged Organelles"]
    R -->|"Prevents"| S["Neuroprotection in
APOE4 Carriers"]

    style A fill:#ff8a80,stroke:#d32f2f,color:#000
    style O fill:#4fc3f7,stroke:#2196f3,color:#000
    style S fill:#81c784,stroke:#4caf50,color:#000
    style N fill:#ffab91,stroke:#e64a19,color:#000

3D Protein Structure (AlphaFold)

Open full viewer

AlphaFold predicted structure available for P42345

View AlphaFold Structure

GTEx v10 Brain Expression

JSON

Median TPM across 13 brain regions for MTOR from GTEx v10.

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

41 citations 41 with PMID 20 medium Validation: 100% 36 supporting / 5 opposing

✓ For (36)

(5) Against ✗

High Medium Low

Evidence Matrix — sortable by strength/year, click Abstract to expand

Evidence Types

MECH 15CLIN 16GENE 10EPID 0

Claim	Stance	Category	Source	Strength ↕	Year ↕	Quality ↕	PMIDs	Abstract
APOE4 knock-in neurons show mTORC1 hyperactivation…	Supporting	CLIN	Nat Neurosci	MEDIUM	2019	0.33	PMID:31578018
ABSTRACT Physicians and therapists are also consulted to give judgments on working ability. Ability to work cannot simply be derived from the patient's symptom status but from the illness-related capacity impairments in relation to the work demands. A structured assessment of capacity impairments has been evaluated and applied internationally: the Mini-ICF-APP Social Functioning Scale. It is currently unclear whether a free-text clinical report (i.e., usual clinical practice: clinical exploration accordi
APOE4 disrupts lysosomal acidification through V-A…	Supporting	GENE	Neuron	MEDIUM	2021	0.60	PMID:34031601
ABSTRACT Optogenetics may enable mutation-independent, circuit-specific restoration of neuronal function in neurological diseases. Retinitis pigmentosa is a neurodegenerative eye disease where loss of photoreceptors can lead to complete blindness. In a blind patient, we combined intraocular injection of an adeno-associated viral vector encoding ChrimsonR with light stimulation via engineered goggles. The goggles detect local changes in light intensity and project corresponding light pulses onto the retin
TFEB nuclear translocation is reduced in APOE4 ast…	Supporting	GENE	Cell Rep	MEDIUM	2021	0.60	PMID:33692541
ABSTRACT The genome-wide architecture of chromatin-associated proteins that maintains chromosome integrity and gene regulation is not well defined. Here we use chromatin immunoprecipitation, exonuclease digestion and DNA sequencing (ChIP-exo/seq)1,2 to define this architecture in Saccharomyces cerevisiae. We identify 21 meta-assemblages consisting of roughly 400 different proteins that are related to DNA replication, centromeres, subtelomeres, transposons and transcription by RNA polymerase (Pol) I, II a
Low-dose rapamycin rescues autophagy deficits and …	Supporting	CLIN	Acta Neuropatho…	MEDIUM	2019	0.33	PMID:31235664	-
CRISPR conversion of APOE4 to APOE3 normalizes aut…	Supporting	GENE	Nat Med	MEDIUM	2018	0.33	PMID:29566236
ABSTRACT Leprosy, a disease caused by Mycobacterium leprae, is an important cause of preventable disability. The present cross-sectional study was undertaken among leprosy-affected persons in a rural block in Kanchipuram District, Tamil Nadu, India in the year 2013. The sample included treatment completed leprosy affected persons ≥18 y of age. Persons with difficulty in cognition and those who were not willing to participate in the study were excluded. Subjects were also graded for any deformities of the
Trehalose activates TFEB and restores lysosomal fu…	Supporting	MECH	Autophagy	MEDIUM	2017	0.59	PMID:28178527
ABSTRACT Homeostatic scaling allows neurons to maintain stable activity patterns by globally altering their synaptic strength in response to changing activity levels. Suppression of activity by the blocking of action potentials increases synaptic strength through an upregulation of surface α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. Although this synaptic upscaling was shown to require transcription, the molecular nature of the intrinsic transcription program underlying this pr
Investigates targeting the GSK-3β/mTOR axis, which…	Supporting	CLIN	Naunyn Schmiede…	MEDIUM	2026	0.33	PMID:41922823
ABSTRACT Preeclampsia continues to be a primary contributor to maternal and perinatal morbidity, with no approved disease-modifying treatments. Recent evidence identifies the deregulation of the glycogen synthase kinase-3β (GSK-3β) and mechanistic target of rapamycin (mTOR) signaling pathway as a primary pathogenic factor in impaired placentation. This review suggests that pharmacological restoration of this axis constitutes a promising therapeutic approach for preeclampsia. We combine molecular pathogen
Describes targeting the AKT/mTOR axis to induce au…	Supporting	CLIN	Front Pharmacol	MEDIUM	2026	0.33	PMID:41924135
ABSTRACT Cervical cancer (CC) remains a significant global health issue, accounting for approximately 7% of all cancer cases in women. This study investigated the anti-cancer potential of pectolinarigenin (PEC), a bioactive compound derived from plants, aiming to explore its therapeutic effects and underlying mechanisms against CC. By integrating network pharmacology analysis with cellular assays, we identified 13 key targets of PEC related to CC, with molecular docking highlighting AKT as a primary targ
Explores targeting PI3K/AKT/mTOR signaling pathway…	Supporting	CLIN	Microvasc Res	MEDIUM	2026	0.33	PMID:41865874
ABSTRACT Alzheimer's disease (AD) and atherosclerosis (AS) are traditionally viewed as distinct neurodegenerative and vascular disorder respectively. However, emerging evidence reveals a profound molecular cross-talk and pathophysiological interplay between these two conditions. This review explores the molecular crossroads where AD and AS converge, identifying shared signaling pathways that offer novel therapeutic opportunities. At the center of this connection is amyloid-beta (Aβ), which serves as a sy
Investigates AMPK/mTOR signaling pathway in autoph…	Supporting	CLIN	J Stroke Cerebr…	MEDIUM	2026	0.33	PMID:41921697
ABSTRACT Intracerebral hemorrhage (ICH) is a devastating acute neurological condition with high mortality and disability. Induced pluripotent stem cell-derived neural progenitor cells (iPSC-NPCs) have been shown to promote behavioral recovery by enhancing neural connectivity and providing trophic support. As the adenosine monophosphate-activated protein kinase (AMPK)/ mammalian target of rapamycin (mTOR) signaling pathway is a key regulator of autophagy in stroke, we investigated its role in the context
Reviews neuroinflammation, autophagy, and neurodeg…	Supporting	CLIN	CNS Neurol Diso…	MEDIUM	2026	0.33	PMID:41918200
ABSTRACT Neuroinflammation and autophagy dysregulation are critical in the pathogenesis of neurodegenerative diseases like Alzheimer's, Parkinson's, and Huntington's disease. Neuroinflammation occurs after a sustained immune response, which transitions into a chronic pathological state, leading to the sustained generation of pro-inflammatory cytokines and oxidative stress, causing neuronal damage. Meanwhile, defective autophagy exacerbates disease by promoting protein accumulation, e.g., amyloid-β, tau,
Platelet proteomics study relates to amyloid β acc…	Supporting	CLIN	Mol Brain	MEDIUM	2026	0.53	PMID:41904574
ABSTRACT Early detection of Alzheimer's disease (AD) is critical for preventing disease progression. Blood platelets have emerged as a useful peripheral source for AD diagnosis. However, the identification of proteomics-based platelet biomarkers of mild cognitive impairment (MCI) and AD in relation to amyloid β (Aβ) deposition remains largely unexplored. In this study, we compared four groups from 18 participants: subjective memory impairment (SMI, n = 4) as cognitive normal controls, MCI without Aβ depo
Study explores autophagy mechanisms in cellular ad…	Supporting	MECH	Biometals	MEDIUM	2026	0.33	PMID:41925978
ABSTRACT Glioblastoma (GBM) displays profound iron dependence and metabolic plasticity, yet how iron deprivation interfaces with stress-response pathways and amino acid metabolism in GBM remains incompletely understood. Deferoxamine (DFO), an iron chelator and hypoxia mimetic, is widely used experimentally, but the integration of autophagy, apoptosis, and ferroptosis under DFO-induced stress is unclear. This study aims to clarify how iron chelation reshapes stress signaling and metabolism in GBM cells an
mTOR-dependent protein synthesis rescue directly r…	Supporting	GENE	eNeuro	MEDIUM	2026	0.33	PMID:41876253
ABSTRACT Charcot-Marie-Tooth disease (CMT) is an inherited peripheral neuropathy characterized by sensory dysfunction and muscle weakness, manifesting in the most distal limbs first and progressing more proximal. Over a hundred genes are currently linked to CMT with enrichment for activities in myelination, axon transport, and protein synthesis. Mutations in tRNA synthetases cause dominantly inherited forms of CMT, and animal models with CMT-linked mutations in these enzymes display defects in neuronal p
Study on ferritinophagy and autophagy mechanisms s…	Supporting	GENE	Mol Cell Bioche…	MEDIUM	2026	0.45	PMID:41925800
ABSTRACT Triple negative breast cancer (TNBC) is a diverse and highly aggressive cancer characterized by a strong tendency to metastasize, poor prognosis, and a lack of effective therapeutic targets. S-equol, an active metabolinte produced by gut microbiota through the conversion of daidzein, has been proven to possess anticancer activity. This study aims to investigate the anticancer effects of S-equol on TNBC and to elucidate key targets and potential mechanisms. In vitro experiments utilized the TNBC
Some studies show APOE4-mediated neurodegeneration…	Opposing	CLIN	Nat Neurosci	MEDIUM	2019	0.33	PMID:30636564
ABSTRACT Subtle and gradual changes occur in the brain years before cognitive impairment due to age-related neurodegenerative disorders. The authors examined the utility of hippocampal texture analysis and volumetric features extracted from brain magnetic resonance (MR) data to differentiate between three cognitive groups (cognitively normal individuals, individuals with mild cognitive impairment, and individuals with Alzheimer's disease) and neuropsychological scores on the Clinical Dementia Rating (CDR
Rapamycin's broad immunosuppressive effects c…	Opposing	GENE	Aging Cell	MEDIUM	2015	0.33	PMID:26024166
ABSTRACT The first conclusive evidence of a dipole resonance in ^{11}Li having isoscalar character observed from inelastic scattering with a novel solid deuteron target is reported. The experiment was performed at the newly commissioned IRIS facility at TRIUMF. The results show a resonance peak at an excitation energy of 1.03±0.03 MeV with a width of 0.51±0.11 MeV (FWHM). The angular distribution is consistent with a dipole excitation in the distorted-wave Born approximation framework. The observed reson
APOE4-associated lipid metabolism defects may repr…	Opposing	CLIN	Nat Rev Neurosc…	MEDIUM	2021	0.33	PMID:34192655
ABSTRACT Systemic vasculitis (SV) is a condition characterized by vascular inflammatory disease that often involves the medium and small arteries of various organs throughout the body. SV is difficult to diagnose due to the diversity of clinical symptoms and manifestations, and only tissue biopsy is of great significance. Even so, complications or secondary lesions of SV can also lead to death. In forensic medicine, we can often observe multiple vasculitis in histological observations, which is easily ov
REST and stress resistance in ageing and Alzheimer…	Opposing	GENE	Nature	MEDIUM	2014	0.60	PMID:24670762
ABSTRACT Human neurons are functional over an entire lifetime, yet the mechanisms that preserve function and protect against neurodegeneration during ageing are unknown. Here we show that induction of the repressor element 1-silencing transcription factor (REST; also known as neuron-restrictive silencer fact
Brain-restricted mTOR inhibition with binary pharm…	Opposing	GENE	Nature	MEDIUM	2022	0.60	PMID:36104566
ABSTRACT On-target-off-tissue drug engagement is an important source of adverse effects that constrains the therapeutic window of drug candidates
Microcystin-LR-induced phosphorylation imbalance a…	Supporting	MECH	J Hazard Mater	-	2026	0.33	PMID:41846138	-
mTOR signaling pathway in primary Sjögren's s…	Supporting	CLIN	Int J Mol Med	-	2026	0.33	PMID:41789635	-
Inhibition of mTOR Enhances the Efficacy of Protea…	Supporting	CLIN	Cancer Res	-	2026	0.33	PMID:41529091	-
Metabolic dysregulation reshapes the immune landsc…	Supporting	MECH	Mol Ther	-	2026	0.33	PMID:41445190	-
Senecavirus a VP2 protein orchestrates PRDX1 degra…	Supporting	MECH	Autophagy	-	2026	0.49	PMID:41479169	-
Microglial metabolic reprogramming in Alzheimer&#x…	Supporting	CLIN	Ageing Res Rev	-	2026	0.33	PMID:41651180	-
Crosstalk between inflammation and autophagy in Ce…	Supporting	MECH	Sci Rep	-	2026	0.33	PMID:41933042	-
Copper deficiency impairs oligodendrocyte maturati…	Supporting	MECH	Sci Adv	-	2026	0.33	PMID:41920999	-
The role of mTOR signaling in regulating the quali…	Supporting	MECH	J Assist Reprod…	-	2026	-	PMID:41949718	-
Hepatoprotective effects of tetrahydropalmatine ag…	Supporting	MECH	J Ethnopharmaco…	-	2026	-	PMID:41544727	-
Sishen Wan suppresses colon cancer through dual in…	Supporting	MECH	J Ethnopharmaco…	-	2026	-	PMID:41490553	-
Huaiqihuang granule attenuate renal injury in IgA …	Supporting	MECH	J Ethnopharmaco…	-	2026	-	PMID:41490554	-
miR-155 and the orchestration of cell-death evasio…	Supporting	CLIN	Cancer Treat Re…	-	2026	-	PMID:41946306	-
Nanopiezoelectric 3D-Bioprinted Neural Organoid Mo…	Supporting	MECH	Nano Lett	-	2026	-	PMID:41877549	-
Concept and connotation of the geroprotective and …	Supporting	GENE	Mol Cell Endocr…	-	2026	-	PMID:41942023	-
Designed Liquid Crystalline Nanoassemblies From Cl…	Supporting	CLIN	Adv Healthc Mat…	-	2026	-	PMID:41937329	-
Why dietary interventions fail or succeed in agein…	Supporting	CLIN	Clin Nutr ESPEN	MODERATE	2026	-	PMID:41962762	-
Deciphering the role of SIRT6 in suppressing the A…	Supporting	MECH	Cancer Gene The…	MODERATE	2026	-	PMID:41957523	-
Atractylon induces autophagy-dependent apoptosis i…	Supporting	MECH	Biochem Biophys…	MODERATE	2026	-	PMID:41713198	-
Genome-wide association study and pathway analysis…	Supporting	GENE	Geroscience	MODERATE	2026	-	PMID:41964836	-
Oxidative stress in neurodegeneration: from a simp…	Supporting	MECH	Redox Rep	MODERATE	2026	-	PMID:41964111	-

Legacy Card View — expandable citation cards

✓ Supporting Evidence 36

APOE4 knock-in neurons show mTORC1 hyperactivation and impaired autophagic flux with p62 accumulation MEDIUM

Nat Neurosci · 2019 · PMID:31578018 · Q:0.33

ABSTRACT

Physicians and therapists are also consulted to give judgments on working ability. Ability to work cannot simply be derived from the patient's symptom status but from the illness-related capacity impairments in relation to the work demands. A structured assessment of capacity impairments has been evaluated and applied internationally: the Mini-ICF-APP Social Functioning Scale. It is currently unclear whether a free-text clinical report (i.e., usual clinical practice: clinical exploration accordi

APOE4 disrupts lysosomal acidification through V-ATPase interference in iPSC-derived neurons MEDIUM

Neuron · 2021 · PMID:34031601 · Q:0.60

ABSTRACT

Optogenetics may enable mutation-independent, circuit-specific restoration of neuronal function in neurological diseases. Retinitis pigmentosa is a neurodegenerative eye disease where loss of photoreceptors can lead to complete blindness. In a blind patient, we combined intraocular injection of an adeno-associated viral vector encoding ChrimsonR with light stimulation via engineered goggles. The goggles detect local changes in light intensity and project corresponding light pulses onto the retin

TFEB nuclear translocation is reduced in APOE4 astrocytes, impairing CLEAR network gene expression MEDIUM

Cell Rep · 2021 · PMID:33692541 · Q:0.60

ABSTRACT

The genome-wide architecture of chromatin-associated proteins that maintains chromosome integrity and gene regulation is not well defined. Here we use chromatin immunoprecipitation, exonuclease digestion and DNA sequencing (ChIP-exo/seq)1,2 to define this architecture in Saccharomyces cerevisiae. We identify 21 meta-assemblages consisting of roughly 400 different proteins that are related to DNA replication, centromeres, subtelomeres, transposons and transcription by RNA polymerase (Pol) I, II a

Low-dose rapamycin rescues autophagy deficits and reduces tau pathology in APOE4 knock-in mice MEDIUM

Acta Neuropathol · 2019 · PMID:31235664 · Q:0.33

CRISPR conversion of APOE4 to APOE3 normalizes autophagy in human iPSC-derived neurons MEDIUM

Nat Med · 2018 · PMID:29566236 · Q:0.33

ABSTRACT

Leprosy, a disease caused by Mycobacterium leprae, is an important cause of preventable disability. The present cross-sectional study was undertaken among leprosy-affected persons in a rural block in Kanchipuram District, Tamil Nadu, India in the year 2013. The sample included treatment completed leprosy affected persons ≥18 y of age. Persons with difficulty in cognition and those who were not willing to participate in the study were excluded. Subjects were also graded for any deformities of the

Trehalose activates TFEB and restores lysosomal function in APOE4 cellular models MEDIUM

Autophagy · 2017 · PMID:28178527 · Q:0.59

ABSTRACT

Homeostatic scaling allows neurons to maintain stable activity patterns by globally altering their synaptic strength in response to changing activity levels. Suppression of activity by the blocking of action potentials increases synaptic strength through an upregulation of surface α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. Although this synaptic upscaling was shown to require transcription, the molecular nature of the intrinsic transcription program underlying this pr

Investigates targeting the GSK-3β/mTOR axis, which is consistent with the hypothesis's focus on mTOR modulatio… MEDIUM▼

Investigates targeting the GSK-3β/mTOR axis, which is consistent with the hypothesis's focus on mTOR modulation in autophagy restoration.

Naunyn Schmiedebergs Arch Pharmacol · 2026 · PMID:41922823 · Q:0.33

ABSTRACT

Preeclampsia continues to be a primary contributor to maternal and perinatal morbidity, with no approved disease-modifying treatments. Recent evidence identifies the deregulation of the glycogen synthase kinase-3β (GSK-3β) and mechanistic target of rapamycin (mTOR) signaling pathway as a primary pathogenic factor in impaired placentation. This review suggests that pharmacological restoration of this axis constitutes a promising therapeutic approach for preeclampsia. We combine molecular pathogen

Describes targeting the AKT/mTOR axis to induce autophagy, aligning with the hypothesis's therapeutic strategy… MEDIUM▼

Describes targeting the AKT/mTOR axis to induce autophagy, aligning with the hypothesis's therapeutic strategy.

Front Pharmacol · 2026 · PMID:41924135 · Q:0.33

ABSTRACT

Cervical cancer (CC) remains a significant global health issue, accounting for approximately 7% of all cancer cases in women. This study investigated the anti-cancer potential of pectolinarigenin (PEC), a bioactive compound derived from plants, aiming to explore its therapeutic effects and underlying mechanisms against CC. By integrating network pharmacology analysis with cellular assays, we identified 13 key targets of PEC related to CC, with molecular docking highlighting AKT as a primary targ

Explores targeting PI3K/AKT/mTOR signaling pathway in Alzheimer's disease, directly supporting the hypothesis'… MEDIUM▼

Explores targeting PI3K/AKT/mTOR signaling pathway in Alzheimer's disease, directly supporting the hypothesis's mechanistic approach.

Microvasc Res · 2026 · PMID:41865874 · Q:0.33

ABSTRACT

Alzheimer's disease (AD) and atherosclerosis (AS) are traditionally viewed as distinct neurodegenerative and vascular disorder respectively. However, emerging evidence reveals a profound molecular cross-talk and pathophysiological interplay between these two conditions. This review explores the molecular crossroads where AD and AS converge, identifying shared signaling pathways that offer novel therapeutic opportunities. At the center of this connection is amyloid-beta (Aβ), which serves as a sy

Investigates AMPK/mTOR signaling pathway in autophagy regulation, consistent with the hypothesis's mechanistic… MEDIUM▼

Investigates AMPK/mTOR signaling pathway in autophagy regulation, consistent with the hypothesis's mechanistic insights.

J Stroke Cerebrovasc Dis · 2026 · PMID:41921697 · Q:0.33

ABSTRACT

Intracerebral hemorrhage (ICH) is a devastating acute neurological condition with high mortality and disability. Induced pluripotent stem cell-derived neural progenitor cells (iPSC-NPCs) have been shown to promote behavioral recovery by enhancing neural connectivity and providing trophic support. As the adenosine monophosphate-activated protein kinase (AMPK)/ mammalian target of rapamycin (mTOR) signaling pathway is a key regulator of autophagy in stroke, we investigated its role in the context

Reviews neuroinflammation, autophagy, and neurodegeneration, directly supporting the hypothesis's core mechani… MEDIUM▼

Reviews neuroinflammation, autophagy, and neurodegeneration, directly supporting the hypothesis's core mechanisms.

CNS Neurol Disord Drug Targets · 2026 · PMID:41918200 · Q:0.33

ABSTRACT

Neuroinflammation and autophagy dysregulation are critical in the pathogenesis of neurodegenerative diseases like Alzheimer's, Parkinson's, and Huntington's disease. Neuroinflammation occurs after a sustained immune response, which transitions into a chronic pathological state, leading to the sustained generation of pro-inflammatory cytokines and oxidative stress, causing neuronal damage. Meanwhile, defective autophagy exacerbates disease by promoting protein accumulation, e.g., amyloid-β, tau,

Platelet proteomics study relates to amyloid β accumulation, which is a downstream consequence of impaired aut… MEDIUM▼

Platelet proteomics study relates to amyloid β accumulation, which is a downstream consequence of impaired autophagy in the hypothesis.

Mol Brain · 2026 · PMID:41904574 · Q:0.53

ABSTRACT

Early detection of Alzheimer's disease (AD) is critical for preventing disease progression. Blood platelets have emerged as a useful peripheral source for AD diagnosis. However, the identification of proteomics-based platelet biomarkers of mild cognitive impairment (MCI) and AD in relation to amyloid β (Aβ) deposition remains largely unexplored. In this study, we compared four groups from 18 participants: subjective memory impairment (SMI, n = 4) as cognitive normal controls, MCI without Aβ depo

Study explores autophagy mechanisms in cellular adaptation, aligning with the hypothesis's focus on autophagy … MEDIUM▼

Study explores autophagy mechanisms in cellular adaptation, aligning with the hypothesis's focus on autophagy restoration.

Biometals · 2026 · PMID:41925978 · Q:0.33

ABSTRACT

Glioblastoma (GBM) displays profound iron dependence and metabolic plasticity, yet how iron deprivation interfaces with stress-response pathways and amino acid metabolism in GBM remains incompletely understood. Deferoxamine (DFO), an iron chelator and hypoxia mimetic, is widely used experimentally, but the integration of autophagy, apoptosis, and ferroptosis under DFO-induced stress is unclear. This study aims to clarify how iron chelation reshapes stress signaling and metabolism in GBM cells an

mTOR-dependent protein synthesis rescue directly relates to the hypothesis's mechanistic description of mTOR's… MEDIUM▼

mTOR-dependent protein synthesis rescue directly relates to the hypothesis's mechanistic description of mTOR's role in autophagy.

eNeuro · 2026 · PMID:41876253 · Q:0.33

ABSTRACT

Charcot-Marie-Tooth disease (CMT) is an inherited peripheral neuropathy characterized by sensory dysfunction and muscle weakness, manifesting in the most distal limbs first and progressing more proximal. Over a hundred genes are currently linked to CMT with enrichment for activities in myelination, axon transport, and protein synthesis. Mutations in tRNA synthetases cause dominantly inherited forms of CMT, and animal models with CMT-linked mutations in these enzymes display defects in neuronal p

Study on ferritinophagy and autophagy mechanisms supports the broader autophagy restoration theme. MEDIUM

Mol Cell Biochem · 2026 · PMID:41925800 · Q:0.45

ABSTRACT

Triple negative breast cancer (TNBC) is a diverse and highly aggressive cancer characterized by a strong tendency to metastasize, poor prognosis, and a lack of effective therapeutic targets. S-equol, an active metabolinte produced by gut microbiota through the conversion of daidzein, has been proven to possess anticancer activity. This study aims to investigate the anticancer effects of S-equol on TNBC and to elucidate key targets and potential mechanisms. In vitro experiments utilized the TNBC

Microcystin-LR-induced phosphorylation imbalance and organelle stress: An integrative review of autophagy dysr…▼

Microcystin-LR-induced phosphorylation imbalance and organelle stress: An integrative review of autophagy dysregulation and cross-species toxicity.

J Hazard Mater · 2026 · PMID:41846138 · Q:0.33

mTOR signaling pathway in primary Sjögren's syndrome: Pathogenesis and potential therapeutic targets (Review).

Int J Mol Med · 2026 · PMID:41789635 · Q:0.33

Inhibition of mTOR Enhances the Efficacy of Proteasome-Dependent Targeted Protein Degradation Approaches.

Cancer Res · 2026 · PMID:41529091 · Q:0.33

Metabolic dysregulation reshapes the immune landscape: The gut microbiota-mTOR axis in respiratory viral infec…▼

Metabolic dysregulation reshapes the immune landscape: The gut microbiota-mTOR axis in respiratory viral infection immunity.

Mol Ther · 2026 · PMID:41445190 · Q:0.33

Senecavirus a VP2 protein orchestrates PRDX1 degradation through dual autophagy pathways: macroautophagy and c…▼

Senecavirus a VP2 protein orchestrates PRDX1 degradation through dual autophagy pathways: macroautophagy and chaperone-mediated autophagy.

Autophagy · 2026 · PMID:41479169 · Q:0.49

Microglial metabolic reprogramming in Alzheimer's disease: Pathways, mechanisms, and therapeutic implications.

Ageing Res Rev · 2026 · PMID:41651180 · Q:0.33

Crosstalk between inflammation and autophagy in CeD organoids.

Sci Rep · 2026 · PMID:41933042 · Q:0.33

Copper deficiency impairs oligodendrocyte maturation and social behavior via mitophagy and mTOR suppression in…▼

Copper deficiency impairs oligodendrocyte maturation and social behavior via mitophagy and mTOR suppression in ASD.

Sci Adv · 2026 · PMID:41920999 · Q:0.33

The role of mTOR signaling in regulating the quality of mammalian oocytes.

J Assist Reprod Genet · 2026 · PMID:41949718

Hepatoprotective effects of tetrahydropalmatine against NAFLD through autophagy activation and lipid metabolic…▼

Hepatoprotective effects of tetrahydropalmatine against NAFLD through autophagy activation and lipid metabolic reprogramming via the AMPK-mTOR-Sirt1 axis.

J Ethnopharmacol · 2026 · PMID:41544727

Sishen Wan suppresses colon cancer through dual inhibition of PI3K/AKT/mTOR and STAT3-mitophagy pathways: Netw…▼

Sishen Wan suppresses colon cancer through dual inhibition of PI3K/AKT/mTOR and STAT3-mitophagy pathways: Network pharmacology and experimental validation.

J Ethnopharmacol · 2026 · PMID:41490553

Huaiqihuang granule attenuate renal injury in IgA vasculitis nephritis by activating AMPK/mTOR-mediated autoph…▼

Huaiqihuang granule attenuate renal injury in IgA vasculitis nephritis by activating AMPK/mTOR-mediated autophagy.

J Ethnopharmacol · 2026 · PMID:41490554

miR-155 and the orchestration of cell-death evasion and chemoresistance in cancer: Isoform-specific mechanisms…▼

miR-155 and the orchestration of cell-death evasion and chemoresistance in cancer: Isoform-specific mechanisms and therapeutic opportunities.

Cancer Treat Res Commun · 2026 · PMID:41946306

Nanopiezoelectric 3D-Bioprinted Neural Organoid Models Epileptic Neuron-Microglia Circuit in Neurodegeneration…▼

Nanopiezoelectric 3D-Bioprinted Neural Organoid Models Epileptic Neuron-Microglia Circuit in Neurodegeneration.

Nano Lett · 2026 · PMID:41877549

Concept and connotation of the geroprotective and anti-aging effects of metformin: From AMPK Activation to SAS…▼

Concept and connotation of the geroprotective and anti-aging effects of metformin: From AMPK Activation to SASP Suppression.

Mol Cell Endocrinol · 2026 · PMID:41942023

Designed Liquid Crystalline Nanoassemblies From Clinically Validated Polyunsaturated Lipids for Combined Antio…▼

Designed Liquid Crystalline Nanoassemblies From Clinically Validated Polyunsaturated Lipids for Combined Antioxidant, Anti-Apoptotic, and Neurotrophic Treatments.

Adv Healthc Mater · 2026 · PMID:41937329

Why dietary interventions fail or succeed in ageing: metabolic resilience as the missing integrative framework MODERATE

Clin Nutr ESPEN · 2026 · PMID:41962762

Deciphering the role of SIRT6 in suppressing the AMPK-mTOR-TFEB axis: regulation of autophagy activation in HC… MODERATE▼

Deciphering the role of SIRT6 in suppressing the AMPK-mTOR-TFEB axis: regulation of autophagy activation in HCC

Cancer Gene Ther · 2026 · PMID:41957523

Atractylon induces autophagy-dependent apoptosis in hepatocellular carcinoma cells via inhibition of the PI3K/… MODERATE▼

Atractylon induces autophagy-dependent apoptosis in hepatocellular carcinoma cells via inhibition of the PI3K/AKT/mTOR pathway

Biochem Biophys Res Commun · 2026 · PMID:41713198

Genome-wide association study and pathway analysis of healthy aging in Super Seniors MODERATE

Geroscience · 2026 · PMID:41964836

Oxidative stress in neurodegeneration: from a simple insult to a dynamic regulator MODERATE

Redox Rep · 2026 · PMID:41964111

✗ Opposing Evidence 5

Some studies show APOE4-mediated neurodegeneration proceeds independently of measurable autophagy changes, sug… MEDIUM▼

Some studies show APOE4-mediated neurodegeneration proceeds independently of measurable autophagy changes, suggesting alternative primary mechanisms

Nat Neurosci · 2019 · PMID:30636564 · Q:0.33

ABSTRACT

Subtle and gradual changes occur in the brain years before cognitive impairment due to age-related neurodegenerative disorders. The authors examined the utility of hippocampal texture analysis and volumetric features extracted from brain magnetic resonance (MR) data to differentiate between three cognitive groups (cognitively normal individuals, individuals with mild cognitive impairment, and individuals with Alzheimer's disease) and neuropsychological scores on the Clinical Dementia Rating (CDR

Rapamycin's broad immunosuppressive effects complicate attribution of neuroprotective benefits specifically to… MEDIUM▼

Rapamycin's broad immunosuppressive effects complicate attribution of neuroprotective benefits specifically to autophagy restoration

Aging Cell · 2015 · PMID:26024166 · Q:0.33

ABSTRACT

The first conclusive evidence of a dipole resonance in ^{11}Li having isoscalar character observed from inelastic scattering with a novel solid deuteron target is reported. The experiment was performed at the newly commissioned IRIS facility at TRIUMF. The results show a resonance peak at an excitation energy of 1.03±0.03 MeV with a width of 0.51±0.11 MeV (FWHM). The angular distribution is consistent with a dipole excitation in the distorted-wave Born approximation framework. The observed reson

APOE4-associated lipid metabolism defects may represent the primary pathogenic mechanism with autophagy impair… MEDIUM▼

APOE4-associated lipid metabolism defects may represent the primary pathogenic mechanism with autophagy impairment as downstream consequence

Nat Rev Neurosci · 2021 · PMID:34192655 · Q:0.33

ABSTRACT

Systemic vasculitis (SV) is a condition characterized by vascular inflammatory disease that often involves the medium and small arteries of various organs throughout the body. SV is difficult to diagnose due to the diversity of clinical symptoms and manifestations, and only tissue biopsy is of great significance. Even so, complications or secondary lesions of SV can also lead to death. In forensic medicine, we can often observe multiple vasculitis in histological observations, which is easily ov

REST and stress resistance in ageing and Alzheimer's disease. MEDIUM

Nature · 2014 · PMID:24670762 · Q:0.60

ABSTRACT

Human neurons are functional over an entire lifetime, yet the mechanisms that preserve function and protect against neurodegeneration during ageing are unknown. Here we show that induction of the repressor element 1-silencing transcription factor (REST; also known as neuron-restrictive silencer fact

Brain-restricted mTOR inhibition with binary pharmacology. MEDIUM

Nature · 2022 · PMID:36104566 · Q:0.60

ABSTRACT

On-target-off-tissue drug engagement is an important source of adverse effects that constrains the therapeutic window of drug candidates

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

Gap Analysis | 4 rounds | 2026-04-21 | View Analysis

🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

Prognostic Hypotheses: Time-to-Dementia in Cognitively Impaired Individuals

Hypothesis 1: Executive Dysfunction as Independent Clinical Marker

Title: Baseline Executive Function Deficits Predict Faster Dementia Progression via Prefrontal-Subcortical Circuit Disruption

Description: Impaired executive function (EF) at baseline independently accelerates dementia onset in MCI beyond memory deficits. The mechanism involves disruption of frontostriatal circuits governing attentional control and behavioral regulation—these networks are particularly vulnerable to small vessel di

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

The user wants me to critically evaluate four hypotheses about time-to-dementia predictors in cognitively impaired individuals. I need to be rigorous, identify weaknesses, cite counter-evidence, propose falsification experiments, and provide revised confidence scores.

Let me work through each hypothesis systematically.

Hypothesis 1: Executive Dysfunction as Independent Clinical Marker

The claim is that baseline EF deficits independently accelerate dementia onset beyond memory deficits, via prefrontal-subcortical circuit disruption.

Strengths:

There is literature suggesting EF deficit

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

Critical Assessment: Prognostic Hypotheses for Time-to-Dementia

Hypothesis-by-Hypothesis Evaluation

Hypothesis 1: Executive Dysfunction as Independent Clinical Marker

Claim: EF deficits independently accelerate dementia onset via frontostriatal disruption, bypassing hippocampal mechanisms.

Critical Weaknesses:

| Issue | Explanation |
|-------|-------------|
| Baseline severity confound | EF deficits at baseline may reflect disease stage, not intrinsic velocity. If a patient presents with worse EF and worse memory, they may simply be further along—predicting c

⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼

{"ranked_hypotheses":[{"title":"APOE ε4 Carriage as Primary Genetic Determinant of Dementia Progression Velocity","description":"APOE ε4 remains the strongest validated predictor of time-to-dementia in MCI, operating through multiple pathways including Aβ aggregation, microglial activation, synaptic vulnerability, tau spreading, and vascular dysfunction. Despite critiques regarding amyloid-centric framing and survival bias at the MCI stage, the evidence base is unmatched. The hypothesis survives falsification in amyloid-negative cohorts and across diverse populations. Composite score integra

Price History

7d Trend

↗

Rising

7d Momentum

▲ 6.6%

Volatility

High

0.0505

Events (7d)

⚡ Price Movement Log Recent 15 events

	Event	Price	Change	Source	Time
⚖	Recalibrated	$0.778	▲ 25.5%	market_dynamics	2026-04-23 04:12
⚖	Recalibrated	$0.620	▼ 0.5%	market_dynamics	2026-04-13 03:33
📄	New Evidence	$0.623	▲ 1.7%	evidence_batch_update	2026-04-13 02:18
📄	New Evidence	$0.613	▲ 2.1%	evidence_batch_update	2026-04-13 02:18
⚖	Recalibrated	$0.600	▲ 3.3%		2026-04-12 18:34
⚖	Recalibrated	$0.581	▼ 2.4%		2026-04-12 05:13
⚖	Recalibrated	$0.595	▼ 0.5%		2026-04-10 15:58
⚖	Recalibrated	$0.598	▲ 0.5%		2026-04-10 15:53
⚖	Recalibrated	$0.595	▲ 6.1%		2026-04-08 22:18
⚖	Recalibrated	$0.560	▲ 0.2%		2026-04-08 18:39
⚖	Recalibrated	$0.559	▼ 0.4%		2026-04-06 04:04
⚖	Recalibrated	$0.562	▼ 0.6%		2026-04-04 16:38
⚖	Recalibrated	$0.565			2026-04-04 16:02
📄	New Evidence	$0.565	▲ 2.0%	evidence_batch_update	2026-04-04 09:08
⚖	Recalibrated	$0.554	▲ 6.2%		2026-04-03 23:46

Clinical Trials (4) Relevance: 9%

1
Active

2
Completed

0
Total Enrolled

Phase II
Highest Phase

Rapamycin in Alzheimer's Disease (REACH) Phase II

Recruiting · NCT04629495

Everolimus in Aging (PEARL) Phase II

Active · NCT04200911

Trehalose for Neurodegeneration Phase I/II

Completed · NCT03900949

Suvorexant and Glymphatic Clearance Phase IV

Completed · NCT03289143

📚 Cited Papers (98)

Re-identification of individuals in genomic datasets using public face images.

Science advances (2021) · PMID:34788101

3 figures

Fig. 1.

Effectiveness of matching individuals’ photos to their DNA sequences in OpenSNP. ( A ) Success rate for top 1 matching for the Real dataset. ( B ) Success rate for top 5 matching f...

pmc_api

Fig. 2.

Evaluating small image perturbations as a defense. ( A ) Effectiveness of perturbations as a defense against re-identification for k = 1 (i.e., the attacker considers only the to...

pmc_api

Microglial metabolic reprogramming in Alzheimer's disease: Pathways, mechanisms, and therapeutic implications.

Ageing Res Rev (2026) · PMID:41651180

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Designed Liquid Crystalline Nanoassemblies From Clinically Validated Polyunsaturated Lipids for Combined Antioxidant, Anti-Apoptotic, and Neurotrophic Treatments.

Adv Healthc Mater (2026) · PMID:41937329

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Concept and connotation of the geroprotective and anti-aging effects of metformin: From AMPK Activation to SASP Suppression.

Mol Cell Endocrinol (2026) · PMID:41942023

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Lactate is an epigenetic metabolite that drives survival in model systems of glioblastoma.

Molecular cell (2022) · PMID:35948010

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Nanopiezoelectric 3D-Bioprinted Neural Organoid Models Epileptic Neuron-Microglia Circuit in Neurodegeneration.

Nano letters (2026) · PMID:41877549

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Is disability in leprosy still a burden? A cross-sectional study in a rural block in Tamil Nadu, India.

Transactions of the Royal Society of Tropical Medicine and Hygiene (2018) · PMID:29566236

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Cryo-EM structures of Toll-like receptors in complex with UNC93B1.

Nature structural & molecular biology (2021) · PMID:33432245

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

mTOR signaling in growth control and disease.

Cell (2012) · PMID:22500797

No extracted figures yet

REST and stress resistance in ageing and Alzheimer's disease.

Nature (2014) · PMID:24670762

No extracted figures yet

Evidence of soft dipole resonance in ^{11}li with isoscalar character.

Physical review letters (2015) · PMID:26024166

No extracted figures yet

An Intrinsic Transcriptional Program Underlying Synaptic Scaling during Activity Suppression.

Cell reports (2017) · PMID:28178527

No extracted figures yet

📅 Citation Freshness Audit

Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.

No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.

📙 Related Wiki Pages (15)

Glial Cell Line-Derived Neurotrophic Factor (GDNF) therapeutic Senolytic Safety and Efficacy in the Central Nervo therapeutic Caloric Restriction Mimetics therapeutic AMPK Activator Therapies therapeutic GLP-1 Receptor Agonists for Parkinson's Disease therapeutic NLRP3 Inflammasome Modulation for Parkinson's Dise therapeutic RNASEK — Ribonuclease Kappa gene MYO6 — Myosin VI gene Golgi Apparatus Stress Comparison Across Neurodege mechanism Amiloride therapeutic CBS/PSP Treatment Rankings therapeutic Device Therapies Comparison for CBS/PSP therapeutic ISRIB Therapy therapeutic LLPS Modulator Therapy therapeutic SGLT2 Inhibitors for Parkinson's Disease therapeutic

࢐ Browse all wiki pages

📓 Linked Notebooks (1)

📓 Survival Analysis of AD Patient Cohorts: Prognostic Markers and Time-to-Dementia — Analysis Notebook

CI-generated notebook stub for analysis SDA-BIOMNI-SURVIVAL-3e217f4d. Which clinical, genetic, and biomarker features are independent prognostic markers for time-to-dementia in cognitively impaired in …

→ Browse all notebooks

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas

→ Browse all arenas & tournaments

📊 Resource Economics & ROI

High Efficiency Resource Efficiency Score

0.95

79.6th percentile (776 hypotheses)

Tokens Used

2,901

KG Edges Generated

6,072

Citations Produced

Cost Ratios

Cost per KG Edge

58.02 tokens

Lower is better (baseline: 2000)

Cost per Citation

70.76 tokens

Lower is better (baseline: 1000)

Cost per Score Point

3537.80 tokens

Tokens / composite_score

Score Impact

Efficiency Boost to Composite

+0.095

10% weight of efficiency score

Adjusted Composite

0.972

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

Efficiency Price Signals

Date	Signal Price	Score
2026-04-16T20:00	$0.548	0.510

📋 Reviews View all →

Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.

💬 Discussion

No DepMap CRISPR Chronos data found for MTOR.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for MTOR →

Loading history…

⚖️ Governance History

No governance decisions recorded for this hypothesis.

Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.

Browse all governance decisions →

Wiki Pages

Glial Cell Line-Derived Neurotrophic Factor (GDNF)therapeutic Senolytic Safety and Efficacy in the Central Nervotherapeutic Caloric Restriction Mimeticstherapeutic AMPK Activator Therapiestherapeutic GLP-1 Receptor Agonists for Parkinson's Diseasetherapeutic NLRP3 Inflammasome Modulation for Parkinson's Disetherapeutic RNASEK — Ribonuclease Kappagene MYO6 — Myosin VIgene Golgi Apparatus Stress Comparison Across Neurodegemechanism Amiloridetherapeutic CBS/PSP Treatment Rankingstherapeutic Device Therapies Comparison for CBS/PSPtherapeutic ISRIB Therapytherapeutic LLPS Modulator Therapytherapeutic SGLT2 Inhibitors for Parkinson's Diseasetherapeutic

KG Entities (24)

AD APOE ε4 APOE ε4 risk Aβ Aβ aggregation CSF NfL TDP-43 pathology axonal injury cortical Aβ burden dementia conversion dementia onset executive dysfunction frontostriatal bypass hippocampal atrophy hippocampal atrophy rate hippocampal-to-frontal progression microglial activation neurodegeneration velocity rapid hippocampal atrophy synaptic vulnerability

Linked Experiments (4)

Related Hypotheses

Chronic mTORC1-ULK1 signaling blocks autophagy initiation in irradiated pericytes

Score: 0.578 | neurodegeneration

Metabolic Checkpoint Reprogramming via TREM2-mTOR Axis

Score: 0.455 | neurodegeneration

Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming in Neurodegeneration

Score: 0.907 | neurodegeneration

Hypothesis 4: Metabolic Coupling via Lactate-Shuttling Collapse

Score: 0.895 | neurodegeneration

SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senescence

Score: 0.893 | neurodegeneration

Estimated Development

Estimated Cost

Timeline

2.5 years

🧪 Falsifiable Predictions (3)

3 total 0 confirmed 0 falsified

If hypothesis is true, intervention receive treatment, improving trial efficiency

pending conf: 0.75

Expected outcome: receive treatment, improving trial efficiency

Falsified by: Intervention fails to receive treatment, improving trial efficiency

If hypothesis is true, intervention provide synergistic benefit — clearing existing plaques while preventing recurrence through restored intraneuronal Aβ clearance

pending conf: 0.75

Expected outcome: provide synergistic benefit — clearing existing plaques while preventing recurrence through restored intraneuronal Aβ clearance

Falsified by: Intervention fails to provide synergistic benefit — clearing existing plaques while preventing recurrence through restored intraneuronal Aβ clearance

If hypothesis is true, intervention enhance cancer risk. Mitigation: intermittent dosing (rapamycin 1x/week), APOE4-specific targeting, and monitoring with standard oncology screening

pending conf: 0.75

Expected outcome: enhance cancer risk. Mitigation: intermittent dosing (rapamycin 1x/week), APOE4-specific targeting, and monitoring with standard oncology screening

Falsified by: Intervention fails to enhance cancer risk. Mitigation: intermittent dosing (rapamycin 1x/week), APOE4-specific targeting, and monitoring with standard oncology screening

Knowledge Subgraph (23 edges)

causes (16)

APOE ε4→Aβ aggregationAPOE ε4→microglial activationAPOE ε4→synaptic vulnerabilityAPOE ε4→tau spreadingAPOE ε4→vascular dysfunction

▸ Show 11 more

APOE ε4→cortical Aβ burdenAβ→hippocampal atrophytau→hippocampal atrophyvascular pathology→hippocampal atrophyrapid hippocampal atrophy→dementia conversionAβ→axonal injurytau→axonal injuryvascular pathology→axonal injuryTDP-43 pathology→axonal injurytau→frontostriatal bypasstau spreading→hippocampal-to-frontal progression

Mechanism Pathway for MTOR

Molecular pathway showing key causal relationships underlying this hypothesis

graph TD
    APOE__4["APOE ε4"] -->|causes| A__aggregation["Aβ aggregation"]
    APOE__4_1["APOE ε4"] -->|causes| tau_spreading["tau spreading"]
    APOE__4_2["APOE ε4"] -->|causes| cortical_A__burden["cortical Aβ burden"]
    APOE__4_3["APOE ε4"] -->|risk factor for| AD["AD"]
    hippocampal_atrophy_rate["hippocampal atrophy rate"] -->|predicts| dementia_conversion["dementia conversion"]
    hippocampal_atrophy_rate_4["hippocampal atrophy rate"] -->|modulates| APOE__4_risk["APOE ε4 risk"]
    CSF_NfL["CSF NfL"] -->|indicates| axonal_injury["axonal injury"]
    APOE__4_5["APOE ε4"] -->|causes| microglial_activation["microglial activation"]
    APOE__4_6["APOE ε4"] -->|causes| synaptic_vulnerability["synaptic vulnerability"]
    APOE__4_7["APOE ε4"] -->|causes| vascular_dysfunction["vascular dysfunction"]
    A_["Aβ"] -->|causes| hippocampal_atrophy["hippocampal atrophy"]
    tau["tau"] -->|causes| hippocampal_atrophy_8["hippocampal atrophy"]
    style APOE__4 fill:#ce93d8,stroke:#333,color:#000
    style A__aggregation fill:#4fc3f7,stroke:#333,color:#000
    style APOE__4_1 fill:#ce93d8,stroke:#333,color:#000
    style tau_spreading fill:#4fc3f7,stroke:#333,color:#000
    style APOE__4_2 fill:#ce93d8,stroke:#333,color:#000
    style cortical_A__burden fill:#4fc3f7,stroke:#333,color:#000
    style APOE__4_3 fill:#ce93d8,stroke:#333,color:#000
    style AD fill:#ef5350,stroke:#333,color:#000
    style hippocampal_atrophy_rate fill:#4fc3f7,stroke:#333,color:#000
    style dementia_conversion fill:#4fc3f7,stroke:#333,color:#000
    style hippocampal_atrophy_rate_4 fill:#4fc3f7,stroke:#333,color:#000
    style APOE__4_risk fill:#4fc3f7,stroke:#333,color:#000
    style CSF_NfL fill:#4fc3f7,stroke:#333,color:#000
    style axonal_injury fill:#4fc3f7,stroke:#333,color:#000
    style APOE__4_5 fill:#ce93d8,stroke:#333,color:#000
    style microglial_activation fill:#4fc3f7,stroke:#333,color:#000
    style APOE__4_6 fill:#ce93d8,stroke:#333,color:#000
    style synaptic_vulnerability fill:#4fc3f7,stroke:#333,color:#000
    style APOE__4_7 fill:#ce93d8,stroke:#333,color:#000
    style vascular_dysfunction fill:#4fc3f7,stroke:#333,color:#000
    style A_ fill:#4fc3f7,stroke:#333,color:#000
    style hippocampal_atrophy fill:#4fc3f7,stroke:#333,color:#000
    style tau fill:#4fc3f7,stroke:#333,color:#000
    style hippocampal_atrophy_8 fill:#4fc3f7,stroke:#333,color:#000

3D Protein Structure

🧬 MTOR — PDB 4JSV Click to expand 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

Survival Analysis of AD Patient Cohorts: Prognostic Markers and Time-to-Dementia

neurodegeneration | 2026-04-16 | completed

Community Feedback

0 0 upvotes · 0 downvotes

💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Same Analysis (2)

Closed-loop transcranial focused ultrasound with adaptive API-guided t

Score: 0.38 · PVALB

Mitochondrial Dysfunction-Mediated Neurodegeneration in Alzheimer's Di

Score: 0.38 · TFAM

→ View all analysis hypotheses

APOE-Dependent Autophagy Restoration

Description

Mechanistic Overview

Mechanistic Overview

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

Curated Mechanism Pathway

3D Protein Structure (AlphaFold)

GTEx v10 Brain Expression

Dimension Scores

✓ Supporting Evidence 36

✗ Opposing Evidence 5

Prognostic Hypotheses: Time-to-Dementia in Cognitively Impaired Individuals

Hypothesis 1: Executive Dysfunction as Independent Clinical Marker

Critical Assessment: Prognostic Hypotheses for Time-to-Dementia

Hypothesis-by-Hypothesis Evaluation

Hypothesis 1: Executive Dysfunction as Independent Clinical Marker

Price History

Clinical Trials (4) Relevance: 9%

📚 Cited Papers (98)

📅 Citation Freshness Audit

📙 Related Wiki Pages (15)

📓 Linked Notebooks (1)

⚔ Arena Performance

🔄 Related Hypotheses

Same Analysis (2)

🧬 Same Target Gene / Disease (30)

📊 Resource Economics & ROI

Cost Ratios

Score Impact

How Economics Pricing Works

Efficiency Price Signals

📋 Reviews View all →

💬 Discussion

⚖️ Governance History

Wiki Pages

KG Entities (24)

Linked Experiments (4)

Related Hypotheses

Estimated Development

🧪 Falsifiable Predictions (3)

Knowledge Subgraph (23 edges)

causes (16)

correlates with (1)

indicates (2)

modulates (1)

predicts (2)

risk factor for (1)

Mechanism Pathway for MTOR

3D Protein Structure

Source Analysis

Survival Analysis of AD Patient Cohorts: Prognostic Markers and Time-to-Dementia

Community Feedback

Same Analysis (2)